News
AI’s impact on finance will continue to deepen, but large staffing cuts are an unlikely result, according to a new Vena ...
Exelixis' zanzalintinib/Opdivo combo shows superior efficacy for treating kidney cancer in an expansion cohort of the phase Ib/II STELLAR-002 study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback